EXELIOM BIOSCIENCES
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Holding
- Established
- 2016-01-01
- Employees
- 2
- Market Cap
- -
- Website
- http://www.exeliombio.com
Clinical Trials
2
Active:1
Completed:0
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)EXL01 in the Maintenance of Steroid-induced Clinical Response/Remission in Participants With Mild to Moderate Crohn's Disease
Phase 1
Terminated
- Conditions
- Crohn Disease
- Interventions
- Drug: PlaceboOther: SoC corticosteroid - Induction PeriodOther: SoC corticosteroid - Tapering
- First Posted Date
- 2022-09-15
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Exeliom Biosciences
- Target Recruit Count
- 8
- Registration Number
- NCT05542355
- Locations
- 🇧🇪
CHU de Liege, Liège, Belgium
🇵🇱Zespół Poradni Specjalistycznych REUMED, Lublin, Poland
🇵🇱Centrum Medyczne "Medyk" Sp. zo.o. Sp.K, Rzeszów, Poland
News
No news found